Global Point-of-Care Testing (POCT) Market 2025-2033

Overview

The Global Point-of-Care Testing (POCT) Market comprises diagnostic solutions that enable rapid, near-patient testing across hospitals, clinics, homecare, and decentralized healthcare settings. POCT includes blood glucose monitoring, infectious disease diagnostics, cardiac biomarkers, pregnancy and fertility testing, coagulation monitoring, and other rapid immunoassay and molecular platforms. Rising demand for quick, accurate diagnostics, the expansion of home-based healthcare, and technological advancements in portable devices are key drivers.

According to Phoenix’s Demand Forecast Engine, the global POCT market is projected to grow from USD 38.4 billion in 2025 to approximately USD 64.9 billion by 2033, reflecting a CAGR of ~7.0% (2025–2033). In 2024, North America accounted for the largest share, while Asia Pacific is expected to record the fastest growth due to expanding healthcare infrastructure and rising prevalence of chronic and infectious diseases.

Key Drivers of Market Growth

1. Growing Prevalence of Chronic & Infectious Diseases
   Rising incidence of diabetes, cardiovascular disorders, and infectious diseases such as influenza, HIV, and COVID-19 boosts demand for rapid testing solutions.
2. Shift Toward Decentralized & Home-Based Care
   Increasing adoption of portable and self-use POCT devices enables patient monitoring outside traditional healthcare settings.
3. Technological Advancements
   Development of molecular POCT, digital connectivity, AI-driven analysis, and miniaturized devices enhances speed and accuracy.
4. Rising Healthcare Accessibility in Emerging Markets
   Expansion of primary care facilities and government investments in diagnostics drive adoption in Asia Pacific and Latin America.
5. Faster Clinical Decision-Making
   POCT reduces turnaround time for results, enabling quicker diagnosis and treatment, particularly in emergency and critical care settings.

Market Segmentation

By Product Type

• Blood Glucose Monitoring Kits
• Infectious Disease Testing Kits
• Cardiac Marker Testing Devices
• Coagulation Monitoring Devices
• Pregnancy & Fertility Testing Kits
• Hematology & Hemoglobin Testing
• Urinalysis & Drugs-of-Abuse Testing
• Molecular POCT Platforms
• Others (lipid, electrolyte testing)

By Technology

• Lateral Flow Assays
• Dipsticks
• Molecular Diagnostics
• Immunoassays
• Others

By End-Use

• Hospitals & Clinics
• Homecare & Self-Testing
• Ambulatory Care & Emergency Settings
• Diagnostic Centers & Research Labs

Region-Level Insights

• North America – Largest Market
  High adoption of advanced POCT devices, strong regulatory support, and large diabetic population drive market share.
• Europe
  Focus on early disease detection, adoption of molecular POCT, and well-established healthcare systems support growth.
• Asia Pacific – Fastest Growing
  Rising healthcare investments, expanding diagnostic infrastructure, and growing burden of chronic and infectious diseases fuel adoption.
• Latin America & Middle East & Africa
  Increasing accessibility to portable diagnostics and government-led screening programs enhance growth potential.

Leading Companies in the Market

Key players include:

• Abbott Laboratories
• https://www.siemens-healthineers.com/Roche Diagnostics
• Siemens Healthineers
• Danaher Corporation (Cepheid)
• Becton, Dickinson and Company (BD)
• QuidelOrtho Corporation
• Chembio Diagnostics
• EKF Diagnostics
• Bio-Rad Laboratories
• Sysmex Corporation

These companies compete through product innovation, regulatory approvals, partnerships with healthcare providers, and digital integration of POCT devices.

Strategic Intelligence and AI-Backed Insights

• AI-enabled POCT: Integration of AI for image interpretation and cloud-based result sharing enhances diagnostic accuracy and patient monitoring.
• Connectivity & Data Management: Growth of connected POCT devices supports electronic medical record (EMR) integration and remote physician oversight.
• Molecular POCT: Expansion of PCR-based rapid testing provides high sensitivity for infectious diseases.
• Cost Efficiency: Decentralized testing reduces lab burden, improves turnaround, and lowers hospitalization costs.
• Risks: Regulatory scrutiny, reimbursement challenges, and quality control concerns in emerging markets.

Forecast Snapshot: 2025–2033

Why the Market Remains Critical

• POCT enables rapid, accessible, and cost-effective diagnostics, improving patient outcomes and healthcare efficiency.
• Strong role in chronic disease management and infectious disease control ensures long-term market resilience.
• Expansion of connected and AI-powered POCT aligns with digital healthcare trends.
• Decentralized models reduce pressure on centralized labs, enabling scalable healthcare delivery.

Final Takeaway

The Global Point-of-Care Testing (POCT) Market is poised for significant expansion, supported by rising disease prevalence, technological advancements, and healthcare decentralization. Companies that prioritize AI-enabled solutions, molecular POCT platforms, and connected homecare diagnostics will capture major growth opportunities. Phoenix Research offers actionable insights to support investment, innovation, and market-entry strategies in this high-growth segment.